French study monitors how new antibiotics are used in kids with superbug infections
NCT ID NCT06036628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study observed over 300 children in French hospitals who were treated with newer antibiotics for infections caused by multi-drug resistant bacteria. Researchers tracked which antibiotics were prescribed and whether they matched the bacteria's resistance profile. The goal was to understand real-world prescribing patterns and identify risk factors for resistant infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
306 people
The number who actually took part.
- Started
-
Apr 2023
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
pediatrics patients infected by multi-resistant bacterial, treated by new antibiotics
- Ages
-
Up to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Children under 18 years of age * Hospitalized in France in a hospital center working with the ACTIV/GPIP network * Treated with one or more of the following antibiotics: * Colimycin (Colistimethate sodium) * Cefiderocol * Aztreonam in combination * Ceftolozane-Tazobactam * Ceftazidime-avibactam * Meropenem/vaborbactam * Imipenem/Relebactam * Tigecycline * Daptomycin * Ceftaroline fosamil * Tedizolid phosphate * Fidaxomicin * Ceftobiprole * Dalbavancin In association with a documented infection performed by: * Blood culture * Normally sterile site * Cerebrospinal fluid * Pleural fluid * Pleura * Peritoneum * Joint fluid * Other * Urine sampling if the bacteria was considered responsible for the infection (associated with a leukocyturia ≥10,0000) * Respiratory specimens if the bacteria was considered responsible for the infection * Sampling on material such as:Intubation probe, Orthopedic, Urological, Central Nervous System (CNS),.... * Related to colonization with multidrug-resistant bacteria without documentation. Exclusion Criteria: * Refusal of participation by the patient or his/her parent * Medical history of mucoviscidosis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Antibiotic prescription are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ACTIV
Créteil, 94000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Training may cut dangerous complications when ICU patients need breathing tubes
- Protein and saline mist may cut bleeding risk after tonsil removal
- Can a simple shield keep IVs in place longer for cancer patients?
- Could a simple health chat slash heart disease and cancer risk?
- Could a boric acid dressing soothe Post-Birth pain and speed healing?
- Can we predict superbug evolution in the ICU?